Nick McDonald

Recent Posts by Nick McDonald:

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings – enabling AGC Biologics to provide an in-depth variety of end-to-end cell and gene therapy services at this site.

AGC Biologics Provides Aid to Ukraine


AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.   

Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate


AGC Biologics is producing vaccine materials for early-stage product trials at its Heidelberg facilities

I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project


AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry


AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity


Seattle – September 13, 2021 – AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects. 

Follow Us
Join us on LinkedIn Follow us on Twitter